Want to see AU:LGP full AI Analyst Report?
LGP Stock Chart & Stats
AU$0.10
<AU$0.01(1.67%)
At close: 4:00 PM EST
AU$0.10
<AU$0.01(1.67%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.15
Previous CloseN/A
Volume21.69K
Average Volume (3M)234.87K
Market Cap
AU$57.40M
Enterprise ValueAU$28.30M
Total Cash (Recent Filing)AU$1.42M
Total Debt (Recent Filing)AU$4.69M
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding819,978,700
10 Day Avg. Volume223,605
30 Day Avg. Volume234,865
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside50.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetThe company’s low leverage and sizable equity base provide durable financial flexibility in a capital-intensive industry. A conservative balance sheet reduces refinancing and solvency risk, enabling continued investment in cultivation and GMP manufacturing even through revenue cycles.
Vertical Integration & ExportsOwning cultivation, processing and manufacturing creates control over quality and supply, helping protect margins and compliance. Export capability with local partners diversifies market exposure and supports scale beyond the domestic market, a durable structural advantage in regulated medical cannabis.
Material Historical Revenue Scale-upSustained top-line expansion over several years demonstrates proven commercial execution, distribution reach and product demand. That historical scale builds manufacturing scale and channel relationships that can underpin future growth if margins and cash conversion stabilize.
Bears Say
Recent Revenue Decline & VolatilityThe year-over-year revenue pullback and historical earnings swings reduce visibility into sustainable demand and complicate capacity planning. Persistent top-line volatility risks underutilized fixed costs in cultivation and manufacturing, pressuring margins and long-term return on invested capital.
Negative Free Cash FlowOngoing negative free cash flow, even if improved, implies the business does not consistently self-fund growth and working capital. This increases reliance on external financing or equity and limits the company’s ability to absorb regulatory or market shocks without dilutive or costly capital.
Inconsistent ProfitabilityIntermittent losses and negative operating profit signal margin pressure and sensitivity to non-operating items. Inconsistent profitability undermines reinvestment capacity and raises execution risk for further scaling, making long-term return generation uncertain until margins stabilize.
Little Green Pharma Ltd. News
LGP FAQ
What was Little Green Pharma Ltd.’s price range in the past 12 months?
Little Green Pharma Ltd. lowest share price was AU$0.06 and its highest was AU$0.14 in the past 12 months.
What is Little Green Pharma Ltd.’s market cap?
Little Green Pharma Ltd.’s market cap is AU$57.40M.
When is Little Green Pharma Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Little Green Pharma Ltd.’s earnings last quarter?
Currently, no data Available
Is Little Green Pharma Ltd. overvalued?
According to Wall Street analysts Little Green Pharma Ltd.’s price is currently Undervalued.
Does Little Green Pharma Ltd. pay dividends?
Little Green Pharma Ltd. does not currently pay dividends.
What is Little Green Pharma Ltd.’s EPS estimate?
Little Green Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Little Green Pharma Ltd. have?
Little Green Pharma Ltd. has 819,978,700 shares outstanding.
What happened to Little Green Pharma Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Little Green Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:LGP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Little Green Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.15 (50.00% Upside)
AU$0.15 (50.00% Upside)
Blogger Sentiment
Bullish
AU:LGP Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
10.34%
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Company Description
Little Green Pharma Ltd.
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medicines, various cannabis extracts, tinctures, and active pharmaceutical ingredients (APIs), serving markets both within Australia and internationally.
LGP Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(50.00% Upside)
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―
Options Prices
Currently, No data available
---